Stock Financial Ratios


TXMD / TherapeuticsMD, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price5.85
Volume2,672,900.00
Market Cap ($M)1,241.39
Enterprise Value ($M)1,075.90
Book Value ($M)127.49
Book Value / Share0.65
Price / Book8.30
NCAV ($M)-4.04
NCAV / Share-0.02
Price / NCAV1,020.63
Income Statement (mra) ($M)
Revenue19.36
EBITDA-90.25
Net Income-89.88
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Assets12.07
Liabilities10.88
Quick Ratio0.45
Current Ratio0.53
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.70
Return on Assets (ROA)-8.22
Return on Equity (ROE)-0.70
Identifiers and Descriptors
CUSIP88338N107
Central Index Key (CIK)25743
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
88338N957
88338N907
Share Statistics
Common Shares Outstanding (M)216.43
Scoring Models
Piotroski F Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Additional Paid In Capital Per Share2.62
Cash And Equivalents Per Share0.00
Liabilities Other Non Current Per Share0.00
Accounts Receivable Per Share0.02
Retained Earnings Per Share-1.86
Inventory Finished Goods Per Share0.01
Accumulated Depreciation And Depletion Per Share0.00
Liabilities Current Per Share0.06
Goodwill Per Share0.00
Inventory Per Share0.01
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Liabilities Per Share0.06
Liabilities And Stock Equity Per Share0.82
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Equity Per Share0.76
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Assets Other Current Per Share0.00
Cash Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Assets Other Non Current Per Share0.00
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Intangibles Per Share0.01
Assets Current Per Share0.04
Assets Per Share0.06
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00

Related News Stories

Your Daily Pharma Scoop: Anxious Time For Dynavax Longs, VBL Therapeutics Gets A Boost, Roche Gets 2 FDA Approvals

2017-11-07 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (414-5)

TherapeuticsMD Gets Lift From FDA Leniency

2017-11-07 seekingalpha
TherapeuticsMD will be responsible for running a post-marketing safety study should it receive approval, which will allow for approval a lot earlier than what was expected. (2-0)

Biotech Forum Daily Digest: Why Adamas Is Soaring

2017-11-06 seekingalpha
Biotech had a nice rally on Friday, which allowed the main biotech indices to post a slight gain on the week. (138-1)

TherapeuticsMD's (TXMD) CEO Robert Finizio on Q3 2017 Results - Earnings Call Transcript

2017-11-06 seekingalpha
Good morning, ladies and gentlemen, and thank you for joining us for the TherapeuticsMD regulatory update and third quarter 2017 financial results conference call. Following prepared remarks from the company, we will open the call for questions. (58-0)

BRIEF-TherapeuticsMD announces plan to resubmit the new drug application for TX-004HR

2017-11-06 reuters
* TherapeuticsMD Inc - Division of bone,reproductive & urologic products, US FDA agreed to NDA resubmission for TX-004HR without additional pre-approval study​ (2-0)

CUSIP: 88338N107